EQT Life Sciences co-leads EUR 51 million Series B in Exciva to advance its Alzheimer’s therapy into clinical Phase 2
admin 5 hours agoNew York StateComments Off on EQT Life Sciences co-leads EUR 51 million Series B in Exciva to advance its Alzheimer’s therapy into clinical Phase 21 Views
PressBee – Series B financing will support Exciva’s Phase 2 clinical trial of its lead candidate, Deraphan, for agitation associated with Alzheimer’s disease (AD) Fin
